MAGEA3 and acute myeloid leukemia: We went on to examine expression of MAGEA1, MAGEA3/A6, NY-ESO-1 and XAGE1 in a larger panel of five AML patients treated with decitabine 20mg/m2/day for 5-10 days as a single agent, clinical characteristics are presented in Table 1 (Cohort A).